Novartis Posts Solid 1Q Sales_eastern heal

Over 700,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:

The Quarter That Was

Novartis maintained its 2011 revenue expectations, aiming to post double-digit constant currency growth. Novartis also hopes to increase its operating margins in 2011, despite the pricing pressure, generic competition and decline in H1N1 pandemic flu sales.

Novartis also received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for approving Lucentis for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO) in Europe.

main_pfp_signup_div font-mily: Arial !important; width: 334 background: url(/images/stock-bg.jpg) repeat-x fdfcf8; color: 000000; border: 1px solid BDDFBA /height: 280 background-color: D2EAD2;/pfp_open_close_bar height: 23color: FFFFFF;font-weight: bold;width: 336 background: url(/images/gradbox_orange.gif) repeat-x !importantsample_newsletter width: 200float: left;text-indent: 15height: 2height: 18padding-top: 2sample_newsletter a color: FFFFFFopen_close_panel width: 120float: left; text-align: right;height: 18padding-top: 2sample_newsletter span, open_close_panel span cursor: pointertitle_bar width: 320padding-left: 10/height: 40/font-size: 25font-weight: bold;color: 000000;padding-top: 10 float: leftsummary_text width: 310padding-left: 10padding-right: 10color: 2F2F2F;font-size: 14line-height: 20margin-bottom: 10pfp_question width: 320padding-left: 10padding-top: 10padding-bottom: 3font-size: 18pfp_key_list float: left;font-size: 13width: 305padding-right: 15padding-left: 10line-height: 15color: 2F2F2Fpfp_key_list ul margin-left: 15padding-left: 0margin-top: 3pfp_key_list ul li b, summary_text b, register_div b color: 000000email width:220 color:2F2F2F; height:18register_div float: left;font-size: 14width: 280padding-left: 10color: 2F2F2F;margin-top: 0Submit222 background-color: 4A684E;color: FFFFFF;font-weight: bold;border: 1px solid 99B09C;width: 45cursor: pointer;font-size: 14height: 22padding-bottom: 2register_div label, register_div a font-size: 10inputs_div padding-top: 5/ New Css Added by Saikat and Subhranil dt 09/01/2010 Ticket 5256 /h3.section margin-top: 1emvertical_slide, horizontal_slide background: url(/images/softGreenGrad635.gif) repeat-y !important; /font-weight: bold;/ font-mily: Arial !important; width: 334 height: auto; color: 000000; border: 1px solid BDDFBA; overflow: hiddendiv.marginbottom / Since the Fx.Slide element resets margins, we set a margin on the above element / margin-bottom: 10/ New Css Added by Saikat and Subhranil dt 09/01/2010 Ticket 5256 /

The performance of each of the four segments is discussed below.

INCYAnalyst Report), announced positive data from a late-stage study of JAK inhibitor INC424, which showed significant reduction in spleen size in myelofibrosis (MF) patients treated with INC424 compared to those treated with the best available therapy for MF. Based on the data, Novartis expects to file global regulatory applications for the candidate in the second quarter of 2011.

Important product approvals/label expansions in the first quarter include Gilenya for highly active relapsing-remitting multiple sclerosis (RRMS) in EU, Lucentis in vision loss due to diabetic macular edema in EU, and Menveo for active immunization to prevent invasive meningococcal disease in children aged 2-10 years in the US.

First quarter revenues were up a solid 16% over the prior year to $14.0 billion. Total revenues also edged past the Zacks Consensus Estimate of $13.4 billion, driven by strong performance of newly launched products like Gilenya, Tasigna, Exforge and Lucentis. All the segments performed well in the quarter, reporting strong volume growth, except for the Vaccines and Diagnostic segment, which was down due to a lack of H1N1 pandemic flu sales.

Zacks Investment Research is one of the most highly regarded fNovartis Posts Solid 1Q Sales_eastern healirms in the investment industry. The guiding principle behind our work is that there must be a good reason for brokerage firms to spend billions of dollars a year on stock research. Obviously, these investment experts know something special that may be indicative of the future direction of stock prices. From day one, we were determined to unlock that secret knowledge and make it available to our clients to help them improve their investment results.

Steve Reitmeister, who heads up Zacks.com, invites you to see our most private stock lists. Even during volatile 2010, they closed out 84 double-digit winners. Then, in Q1 2011, there were 41 more!

2011 Guidance

Sandoz division sales were up 16% to $2.3 billion, benefiting from new product launches like the generic version of Eli Lilly’s (

Pharmaceutical division sales were up 7% to $7.8 billion in the quarter. Growth from volume expansion and new product launches (accounting for 25% of pharmaceutical sales) was offset by 2 percentage points of price erosion and negative impact of generic launches. All the franchises performed well in the quarter.

In early April, 2011, Novartis completed the merger with Alcon following which Alcon became the second largest division within Novartis. Moreover, Novartis’ CIBA Vision, select eye care medicines and an Alcon business wing will be integrated into Alcon. This new divisional structure will be implemented from the second quarter of 2011. In the first quarter, Alcon sales rose 12% to $1.9 billion driven mainly by strong sales of pharmaceutical products.

Novartis also received a positive opinion from an FDA panel recommending approval of only the lower 75 mcg dose and not the higher 150 mcg dose of QAB149 for the treatment of chronic obstructive pulmonary disease (COPD). QAB149 is already marketed as Onbrez Breezhaler in more than 50 countries all over the world. QAB149 will be marketed as Arcapta Neohaler in the US, if approved.

Novartis Posts Solid 1Q Sales_eastern heal,NVSSnapshot Report) reported earnings per share of $1.41 for the first quarter of 2011, below the year-earlier earnings of $1.45 per share but well ahead of the Zacks Consensus Estimate of $1.31. The drop from the base period resulted from financing costs for the Alcon acquisition completed in April this year. An increase in the number of shares outstanding, in the quarter, following dilution from the merger also affected earnings. Also marring earnings were robust profits booked in 2009 from windll sales of H1N1 flu vaccines that were not to be repeated in the current quarter.

Galvus (up 74% to $132 million) led the 7% growth in the Cardiovascular and Metabolism franchise. The Neuroscience and Ophthalmics franchise experienced a 16% increase led by Lucentis (up 22% to $444 million) and Extavia (up 70% to $34 million). The franchise also benefited from the strong performance of recently launched multiple sclerosis drug, Gilenya, which recorded revenues of $59 million in the US. Novartis received approval to market Gilenya in the EU in the first quarter. Gilenya has also been approved in Switzerland and Australia.

Our Recommendation

In the quarter, Novartis received a positive recommendation from an advisory panel of the US Food and Drug Administration (FDA) for expanding use of its renal cancer drug Afinitor. The approval is sought for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin, a rare form of pancreatic cancer.

Oncology sales growth of 8% was led by some established products like Gleevec (up 4% to $1.1 billion), Sandostatin (up 9% to $337 million) and Femara (up 3% to $354 million) as well as new products like Tasigna (up 104% to $153 million) and Afinitor (up 120% to $90 million).

Product and Pipeline Update

SNYAnalyst Report) Lovenoeastern health h1n1x and strong biosimilars growth outside Germany. The segment posted strong revenues in the US, Canada, Western Europe, and Central and Eastern Europe, which made up for the decline in Germany due to healthcare cost containment measures.

Consumer Health division sales were up 11% over the prior year at $1.6 billion driven by strong sales of over-the-counter (OTC) products, particularly Prevacid24HR, and the Animal Health business.

In the quarter, Novartis’ partner, Incyte Corporation (

Currently, we have a Neutral recommendation on Novartis, which is supported by a Zacks 3 Rank (short-term Hold rating). We are highly encouraged by the Swiss company’s strong performance in the first quarter. Though pleased with Novartis’ wide range of products and its efforts to diversify further, as is evident by the acquisition of eye-care company Alcon, we prefer to remain on the sidelines due to the imminent patent cliff ced by the company.

The Vaccines and Diagnostics division recorded a sales decline of 73% to $371 million. Depressed sales of H1N1 pandemic flu vaccine in the quarter (due to the waning of the swine flu disease) perpetrated the ll. Excluding the expected decline in H1N1 vaccine sales, the segment grew 43% (in constant currency) driven by growth of the meningitis vaccines (Menveo and MenB).

Leave a Reply